Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 9/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702276 | 0.89 | DRD2 (0.57) | DRD2DRD1DRD3HTR1ADRD4 | |
| SCHEMBL22702312 | 0.89 | DRD2 (0.57) | DRD2DRD1DRD3HTR1ADRD4 | |
| SCHEMBL7785759 | 0.86 | DRD2 (0.47) | DRD2DRD1DRD3HTR1ADRD4 | |
| SCHEMBL7788407 | 0.79 | DRD2 (0.78) | DRD2DRD1DRD3HTR1ADRD4 | |
| SCHEMBL7785685 | 0.79 | DRD2 (0.78) | DRD2DRD1DRD3HTR1ADRD4 | |
| SCHEMBL7785683 | 0.74 | DRD2 (0.43) | DRD2DRD1DRD3HTR1ADRD4 | |
| SCHEMBL7785681 | 0.74 | DRD2 (0.43) | DRD2DRD1DRD3HTR1ADRD4 | |
| SCHEMBL5811739 | 0.67 | DRD2 (0.42) | DRD2DRD1 | |
| SCHEMBL7786294 | 0.66 | DRD2 (0.54) | DRD2DRD3DRD4HTR1DHTR1B | |
| SCHEMBL8126165 | 0.66 | HTR1D (0.64) | DRD2DRD1DRD3HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | DRD2 33/4885DRD1 61/4885DRD3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.